ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.